Safinamide Phase III MOTION and SETTLE study results
to be presented at American Academy of Neurology (AAN) Annual Meeting

Milan, Italy, March 8, 2013 – Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., a pharmaceutical company strongly committed in the respiratory, primary care and CNS therapeutic area, announced today that results from the Phase III studies MOTION and SETTLE will be presented at the 65th Annual Meeting of the American Academy of Neurology (AAN) taking place from March 16–23, 2013, at the San Diego Convention Center, San Diego, CA, USA.

Safinamide Phase III development as add-on treatment to dopamine agonist or levodopa in early to late stage Parkinson’s disease (PD) has been completed. The efficacy and safety of safinamide as add-on to a stable dose of a single dopamine agonist was evaluated in patients with early PD in three placebo-controlled studies (009, 015, MOTION), while its therapeutic benefits as add-on to levodopa and other PD treatments in patients with advanced PD were studied in two placebo-controlled studies (016, SETTLE).

Newron has lately completed its initial series of meetings with European health authorities relating to the results of the preclinical, CMC, and clinical studies to support registration of safinamide as add-on therapy for the treatment of both early (non-fluctuating) and advanced (fluctuating) patients with idiopathic Parkinson’s disease (PD). The Company will proceed to meet with additional European health authorities, EMA and FDA to discuss its plans for regulatory submission in QIV/2013.

The following abstracts have been accepted for presentation at the 65rd AAN Annual Meeting:

**MOTION**
Safinamide as an Add-On Therapy to a Stable Dose of a Single Dopamine Agonist: Results from a Randomized, Placebo-Controlled, 24-Week Multicenter Trial in Early Idiopathic Parkinson Disease (PD) Patients (MOTION Study)
Session P01: Movement Disorders: Parkinson's Disease Therapy
P01.061, Monday, March 18, 2013
Presentation time: 2:00 pm PST
Poster available from 2:00 pm – 6:30 pm PST

**SETTLE**
Safinamide Add on to L-Dopa: A Randomized, Placebo-Controlled, 24-Week Global Trial in Patients with Parkinson's Disease (PD) and Motor Fluctuations (SETTLE)
Session P01: Movement Disorders: Parkinson's Disease Therapy
P01.062, Monday, March 18, 2013
Presentation time: 2:00 pm PST
Poster available from 2:00 pm – 6:30 pm PST
Furthermore, the safinamide results have been chosen by the organizers to be presented as part of the “Movement Disorders Section Highlights in the Field” on Wednesday, March 20, 2013, from 7:30 pm - 8:00 pm PST.

Ravi Anand, Newron’s CMO, stated: “Newron is pleased with the opportunity to present details of the significantly positive results for the MOTION and the SETTLE studies. These results will complete the package of studies that Newron intends to submit for regulatory approval in the US and Europe in QIV/2013”.

Marco Sardina, Zambon’s CSO, stated: “Zambon is pleased to see important positive results fully supporting Zambon’s strategic decision to enter in the Parkinson disease area with a new product that will provide significant patient benefits.”

Abstracts and a release text will be available for download on Newron’s website by March 19, 2013, 07:00 am CET. Furthermore, Newron will host a webcast for investors, analysts and the press on March 19, 2013, 08:30 am CET. Connecting details will be announced by separate release on March 19, 2013.

About safinamide
Safinamide is an alpha-aminoamide is currently being developed by Newron as an add-on therapy to dopamine agonists or to levodopa in patients with early or mid- to late-stage Parkinson’s disease (PD). It is believed to have both dopaminergic and non-dopaminergic activities, including selective and reversible inhibition of monoamine oxidase B (MAO-B), activity-dependent sodium-channel antagonism and inhibition of glutamate release in vitro.

About Newron Pharmaceuticals
Newron (SIX: NWRN) is a biopharmaceutical company focused on novel therapies for diseases of the Central Nervous System (CNS) and pain. The Company is headquartered in Bresso near Milan, Italy. Based on the phase III results of safinamide for treatment of Parkinson’s disease, Newron is working to expedite the global filing of the compound, together with its partners. Zambon Group has the rights to commercialise safinamide globally, excluding Japan and other key Asian territories, and Meiji Seika has the rights to develop and commercialise safinamide in Japan and other key Asian territories. Newron’s additional projects are primarily addressed towards highly promising treatments for rare diseases and are at various stages of preclinical and clinical development, including sNN0031 for Parkinson’s disease, sarizotan for Rett’s syndrome, sNN0029 for ALS, ralfinamide for specific pain indications, and NW-3509 as potential first add-on therapy for the treatment of schizophrenia. www.newron.com

About Zambon
Zambon is a leading Italian pharmaceutical and fine-chemical multinational company, that has earned a strong reputation over the years for high quality products and services. Zambon is well-established in 3 therapeutic areas: respiratory, pain and woman care. Zambon SpA produces high quality products thanks to the management of the whole production chain which involves Zach (Zambon chemical), a privileged partner for API, custom synthesis and generic products. The Group is strongly working on the treatment of the chronic respiratory diseases as BPCO and on the CNS therapeutic area with Safinamide for the Parkinson treatment. Zambon is headquartered in Milan and was established in 1906 in Vicenza. Zambon is present in 15 countries with more than 2,600 employees with manufacturing units in Switzerland, France, China and Brazil.

For details on Zambon please see: www.zambongroup.com
Important Notices
This document contains forward-looking statements, including (without limitation) about (1) Newron’s ability to develop and expand its business, successfully complete development of its current product candidates and current and future collaborations for the development and commercialisation of its product candidates and reduce costs (including staff costs), (2) the market for drugs to treat CNS diseases and pain conditions, (3) Newron’s anticipated future revenues, capital expenditures and financial resources, and (4) assumptions underlying any such statements. In some cases these statements and assumptions can be identified by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, and other words and terms of similar meaning. All statements, other than historical facts, contained herein regarding Newron’s strategy, goals, plans, future financial position, projected revenues and costs and prospects are forward-looking statements.
By their very nature, such statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that predictions, forecasts, projections and other outcomes described, assumed or implied therein will not be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. These factors include (without limitation) (1) uncertainties in the discovery, development or marketing of products, including without limitation negative results of clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing and entry into future collaborations and licensing agreements, (7) litigation, (8) loss of key executive or other employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions.
Newron may not actually achieve the plans, intentions or expectations disclosed in forward-looking statements and assumptions underlying any such statements may prove wrong. Investors should therefore not place undue reliance on them. There can be no assurance that actual results of Newron’s research programmes, development activities, commercialisation plans, collaborations and operations will not differ materially from the expectations set out in such forward-looking statements or underlying assumptions. Newron does not undertake any obligation to publicly up-date or revise forward looking statements except as may be required by applicable regulations of the SIX Swiss Exchange where the shares of Newron are listed.
This document does not contain or constitute an offer or invitation to purchase or subscribe for any securities of Newron and no part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.